2. Academic Validation
  3. Targeting the IDO1 pathway in cancer: from bench to bedside

Targeting the IDO1 pathway in cancer: from bench to bedside

  • J Hematol Oncol. 2018 Aug 2;11(1):100. doi: 10.1186/s13045-018-0644-y.
Ming Liu 1 2,  Xu Wang 3,  Lei Wang 3 4,  Xiaodong Ma 4,  Zhaojian Gong 3 5,  Shanshan Zhang 3 6,  Yong Li 7
Affiliations

Affiliations

  • 1 State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China. [email protected].
  • 2 Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. [email protected].
  • 3 Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
  • 4 Institute for Brain Research and Rehabilitation, South China Normal University, Guangzhou, China.
  • 5 Department of Stomatology, The Second Xiangya Hospital, Central South University, Changsha, China.
  • 6 Department of Stomatology, Xiangya Hospital, Central South University, Changsha, China.
  • 7 Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. [email protected].
PMID: 30068361 DOI: 10.1186/s13045-018-0644-y
Abstract

Indoleamine 2, 3-dioxygenases (IDO1 and IDO2) and tryptophan 2, 3-dioxygenase (TDO) are tryptophan catabolic Enzymes that catalyze the conversion of tryptophan into kynurenine. The depletion of tryptophan and the increase in kynurenine exert important immunosuppressive functions by activating T regulatory cells and myeloid-derived suppressor cells, suppressing the functions of effector T and natural killer cells, and promoting neovascularization of solid tumors. Targeting IDO1 represents a therapeutic opportunity in Cancer Immunotherapy beyond checkpoint blockade or adoptive transfer of chimeric antigen receptor T cells. In this review, we discuss the function of the IDO1 pathway in tumor progression and immune surveillance. We highlight recent preclinical and clinical progress in targeting the IDO1 pathway in Cancer therapeutics, including peptide vaccines, expression inhibitors, enzymatic inhibitors, and effector inhibitors.

Keywords

3-dioxygenases; Clinical trial; IDO1; Immunosuppression; Immunotherapy; Indoleamine 2.

Figures